Literature DB >> 10867265

Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats.

Y Kaneo1, T Ueno, T Tanaka, H Iwase, Y Yamaguchi, T Uemura.   

Abstract

Fluorescein-labeled arabinogalactan (FA) was prepared by the reaction with FITC in methyl sulphoxide according to the method of deBelder and Granath. A systemic kinetic analysis of FA in rats was carried out by using a specific high-performance size-exclusion chromatography. Intravenously administered FA was rapidly eliminated from the blood circulation followed by an appreciable distribution to the liver and kidney. FA was accumulated in these organs over a long period whereas negligible levels of FA were detected in the other organs. A marked dose-dependency was seen in the hepatic uptake of FA which was markedly reduced by coinjected asialofetuin whereas the renal uptake of FA was not altered. Measurement of the hepatocellular localization demonstrated the overwhelming distribution of FA in the parenchymal liver cell fraction. Furthermore, the microscopic examination revealed FA that was effectively endocytosed by the parenchymal liver cells. These results suggested that FA which is bound to the asialoglycoprotein receptor with a high affinity is subsequently internalized to the hepatocyte via receptor-mediated endocytosis. FA was partially activated by periodate oxidation in order to acquire aldehyde groups to which guest molecules can be bound. A 12.5% oxidized arabinogalactan keeping a hepatocellular targetability showed a good conjugating reactivity to guest molecules via Schiff-base formation or by reductive amination. It was suggested that arabinogalactan can serve as a potential carrier for the delivery of enzymes and drugs to the parenchymal liver cells via the asialoglycoprotein receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867265     DOI: 10.1016/s0378-5173(00)00405-1

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  Antitumor effect of arabinogalactan and platinum complex.

Authors:  A K Starkov; T N Zamay; A A Savchenko; E V Ingevatkin; N M Titova; O S Kolovskaya; N A Luzan; P P Silkin; S A Kuznetsova
Journal:  Dokl Biochem Biophys       Date:  2016-05-20       Impact factor: 0.788

2.  Comparative in silico-in vivo evaluation of ASGP-R ligands for hepatic targeting of curcumin Gantrez nanoparticles.

Authors:  Anisha A D'Souza; Puneet Jain; C N Galdhar; Abdul Samad; Mariam S Degani; Padma V Devarajan
Journal:  AAPS J       Date:  2013-04-12       Impact factor: 4.009

3.  Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Vinod C Malshe; Vaishali Pujari; Ajit Gorakshakar; Manisha Madkaikar; Kanjaksha Ghosh; Padma V Devarajan
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

4.  Microanalysis, Pharmacokinetics and Tissue Distribution of Polysaccharide-Protein Complexes from Longan Pulp in Mice.

Authors:  Ting Min; Jie Sun; Yang Yi; Hong-Xun Wang; Fei Hang; You-Wei Ai; Li-Mei Wang
Journal:  Int J Mol Sci       Date:  2015-10-15       Impact factor: 5.923

5.  Schisandra chinensis peptidoglycan-assisted transmembrane transport of lignans uniquely altered the pharmacokinetic and pharmacodynamic mechanisms in human HepG2 cell model.

Authors:  Charng-Cherng Chyau; Yaw-Bee Ker; Chi-Huang Chang; Shiau-Huei Huang; Hui-Er Wang; Chiung-Chi Peng; Robert Y Peng
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

6.  Asialoglycoprotein receptor targeted optical and magnetic resonance imaging and therapy of liver fibrosis using pullulan stabilized multi-functional iron oxide nanoprobe.

Authors:  Ariya Saraswathy; Shaiju S Nazeer; Nirmala Nimi; Hema Santhakumar; Parvathy Radhakrishnapillai Suma; Kunnumpurathu Jibin; Marina Victor; Francis Boniface Fernandez; Sabareeswaran Arumugam; Sachin J Shenoy; P R Harikrishna Varma; Ramapurath S Jayasree
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.